NCT06576076 Cannabis, Linked Emotions, and Adolescent Risk Study
| NCT ID | NCT06576076 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Cannabis Use |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-02-18 |
| Primary Completion | 2029-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-02-18 with a primary completion date of 2029-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to disentangle relationships between acute cannabis use and withdrawal on proximal depression and suicide risk and recovery in adolescents ages 12-18 years by incorporating time-varying patterns of substance use, mood, and SI. This project aims to guide the development of scalable, individualized, accessible, and affordable interventions aimed to reduce depression and suicide risk among adolescents.
Eligibility Criteria
Inclusion Criteria: * Ages 12-18; * Current daily or near daily cannabis use (i.e., use ≥ 4 days per week on average; Timeline Followback); * Score ≥ 5 on PHQ-9; * Access to an internet-capable smartphone (iOS or Android); * Provision of at least 1 collateral contact for risk monitoring; * Provision of informed assent (or consent if 18 years or older) and parent/guardian consent if \<age 18; * Greater than 50% response rate to EMA prompts during the first EMA phase; * No immediate plan to discontinue cannabis use in the next 3 months; * Positive toxicology result for cannabis on baseline urinalysis. Exclusion Criteria: * Any factor that impairs ability to comprehend and effectively participate, including acute intoxication at time of consent; * Cannabis use \>4 times/day on average (to maximize likelihood of capturing mood and SI during non-use times); * Inability to speak/write English fluently; * Gross cognitive impairment, for example due to florid psychosis, intellectual disability, developmental delay, or neurodegenerative disease; * Current epilepsy diagnosis; * Individuals who are under the legal protection of the government or state (wards of the state); * Response of "No" to the knowledge check question regarding EMA suicidality response time; * Inability to wear Fitbit device.
Contact & Investigator
Randi M Schuster, PhD
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06576076 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 18 Years, studying Cannabis Use. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06576076 currently recruiting?
Yes, NCT06576076 is actively recruiting participants. Contact the research team at rschuster@mgh.harvard.edu for enrollment information.
Where is the NCT06576076 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06576076 clinical trial?
NCT06576076 is sponsored by Massachusetts General Hospital. The principal investigator is Randi M Schuster, PhD at Massachusetts General Hospital. The trial plans to enroll 200 participants.